Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients

Fineline Cube May 7, 2026
Policy / Regulatory

CDE Seeks Public Feedback on Latest Batch of Generic Drug Reference Preparations

Fineline Cube Mar 19, 2024

The Center for Drug Evaluation (CDE), a key regulatory body overseeing pharmaceutical evaluations in China,...

Company Drug

AstraZeneca Caps Monthly Costs for US Patients with Asthma and COPD Inhalers

Fineline Cube Mar 19, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced an expansion of its...

Company Drug

Jiangsu Yahong Meditech to Present Phase III Results for Cervical Cancer Treatment at SGO Annual Meeting

Fineline Cube Mar 19, 2024

Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments, is...

Company Medical Device

Sino Medical Sciences Secures South Korean Approvals for Three Cardiovascular Devices

Fineline Cube Mar 19, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced...

Company Deals

Bio-Thera Solutions and SteinCares Ink Licensing Deal for LatAm Biosimilar Distribution

Fineline Cube Mar 19, 2024

Bio-Thera Solutions (SHA: 688177), a Chinese biopharmaceutical company, has entered into a licensing agreement with...

Company Deals

C&Y Pharmaceutical Teams Up with GigaCeuticals to Form AI-Driven Drug Development JV

Fineline Cube Mar 19, 2024

Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254), a Chinese pharmaceutical company, is venturing into...

Company Drug

GSK’s Jemperli Shows Survival Benefits in Phase III Endometrial Cancer Study

Fineline Cube Mar 19, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has presented early results from a...

Company

Akeso Biopharma Reports Record Revenue and First Profit, Driven by Innovative Drugs

Fineline Cube Mar 19, 2024

Akeso Biopharma (HKG: 9926) has announced its financial results for 2023, reporting a record revenue...

Company Deals

uBriGene Partners with XJTLU to Develop CAR-NK Cell Therapies for Solid Tumors

Fineline Cube Mar 18, 2024

uBriGene, a China-based biotechnology company, has entered into a partnership with Xi’an Jiaotong-Liverpool University (XJTLU)...

Company Deals Drug

Boehringer Ingelheim Partners with Sosei Group to Develop GPR52 Agonists for Schizophrenia

Fineline Cube Mar 18, 2024

Boehringer Ingelheim (BI), headquartered in Germany, has entered into a global collaboration and exclusive option-to-license...

Company Drug

BeiGene’s Tislelizumab Receives FDA Approval for Esophageal Squamous Cell Carcinoma

Fineline Cube Mar 18, 2024

BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration (FDA) has granted...

Company Deals

Hansoh Pharmaceutical Secures Global Rights to Biotheus’ BsAb HS-20117/PM1080

Fineline Cube Mar 18, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has...

Company Policy / Regulatory

Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use

Fineline Cube Mar 18, 2024

GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...

Company Drug

Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use

Fineline Cube Mar 18, 2024

GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...

Company Deals

Microenergy Medical Technology Secures Pre-Series A Funding to Advance Medical Devices

Fineline Cube Mar 18, 2024

Microenergy Medical Technology Co., Ltd, a Hangzhou-based manufacturer of active intervention medical devices, has reportedly...

Company Deals

Getein Biotech Partners with Dymind Biotechnology to Advance IVD Market Presence

Fineline Cube Mar 18, 2024

Getein Biotech Inc., (SHA: 603387), a company based in China with a focus on in...

Company Deals

CanSino Biologics Partners with Asymchem Laboratories to Innovate Biopharmaceutical Development

Fineline Cube Mar 18, 2024

CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into...

Company Drug

Simcere Pharmaceutical’s Suvemcitug Files for Approval in China for Recurrent Ovarian Cancer

Fineline Cube Mar 18, 2024

Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that an...

Company Drug

Bristol Myers Squibb’s Breyanzi Receives FDA Accelerated Approval for CLL/SLL Treatment

Fineline Cube Mar 18, 2024

The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s...

Company Drug

Sino Biopharmaceutical Advances Lanifibranor and TQA2225 into Late-Stage Clinical Trials for MASH

Fineline Cube Mar 18, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...

Posts pagination

1 … 383 384 385 … 661

Recent updates

  • Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations
  • BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year
  • Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio
  • Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients
  • Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations

Company

BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year

Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Company Drug

Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.